Feng W. Sun

109 Baoyu Road
Tanjiagang, 400036, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 73 publications

Rifapentine dosing for drug-susceptible tuberculosis: stage 1 of a seamless phase 2/3 randomized clinical trial.

Rifapentine dosing for drug-susceptible tuberculosis: stage 1 of a seamless phase 2/3 randomized clinical trial.

Journal: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

Published: January 22, 2026

QT interval prolongation and cardiotoxicity in shorter regimens for rifampicin-resistant tuberculosis.

QT interval prolongation and cardiotoxicity in shorter regimens for rifampicin-resistant tuberculosis.

Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Published: January 16, 2026

A Novel Therapy With a One-Month Ultrashort Regimen to Halt Progression From Latent Infection to Active Tuberculosis Among Close Contacts (The TB‑YOUTH Study): Protocol for a Cluster Randomized Controlled Trial.

A Novel Therapy With a One-Month Ultrashort Regimen to Halt Progression From Latent Infection to Active Tuberculosis Among Close Contacts (The TB‑YOUTH Study): Protocol for a Cluster Randomized Controlled Trial.

Journal: JMIR research protocols

Published: December 15, 2025

Diagnostic performance of the Sanity 2.0 assay to detect resistance to rifampicin, isoniazid, and fluoroquinolones in tuberculosis.

Diagnostic performance of the Sanity 2.0 assay to detect resistance to rifampicin, isoniazid, and fluoroquinolones in tuberculosis.

Journal: Journal of clinical microbiology

Published: December 10, 2025

A bidimensional early intervention strategy of standard of care in combination with corticosteroids in elderly patients with mild to moderate COVID-19 (BEAT-COV study): a multicentre, open-label, randomized controlled trial.

A bidimensional early intervention strategy of standard of care in combination with corticosteroids in elderly patients with mild to moderate COVID-19 (BEAT-COV study): a multicentre, open-label, randomized controlled trial.

Journal: BMC infectious diseases

Published: December 01, 2025

Durable three-year outcomes and persistent neuropathy following nine-month all-oral regimens for rifampicin-resistant tuberculosis: a multicentre cohort study in China.

Durable three-year outcomes and persistent neuropathy following nine-month all-oral regimens for rifampicin-resistant tuberculosis: a multicentre cohort study in China.

Journal: BMC infectious diseases

Published: November 15, 2025

Comparative efficacy and safety of high-dose rifamycin regimens for tuberculosis treatment: a Bayesian network meta-analysis.

Comparative efficacy and safety of high-dose rifamycin regimens for tuberculosis treatment: a Bayesian network meta-analysis.

Journal: BMJ open

Published: October 05, 2025

A 6- to 9-months oral regimen for rifampicin-resistant tuberculosis: a randomized open-label noninferiority trial in China.

A 6- to 9-months oral regimen for rifampicin-resistant tuberculosis: a randomized open-label noninferiority trial in China.

Journal: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

Published: August 14, 2025

Repeat detection of Mycobacterium DNA in sputum for the diagnosis of pulmonary tuberculosis.

Repeat detection of Mycobacterium DNA in sputum for the diagnosis of pulmonary tuberculosis.

Journal: Medicine

Published: June 17, 2025

Treatment of asymptomatic tuberculosis: Protocol for a systematic review of treatment strategies, regimens, and clinical outcomes.

Treatment of asymptomatic tuberculosis: Protocol for a systematic review of treatment strategies, regimens, and clinical outcomes.

Journal: PloS one

Published: June 09, 2025

Acquired resistance during short-course treatment for rifampicin-resistant tuberculosis.

Acquired resistance during short-course treatment for rifampicin-resistant tuberculosis.

Journal: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

Published: April 14, 2025

Innovating shorter, all-oral, precise, individualized treatment regimen for rifampicin-resistant tuberculosis (INSPIRE TB): study protocol for a pragmatic randomised controlled trial.

Innovating shorter, all-oral, precise, individualized treatment regimen for rifampicin-resistant tuberculosis (INSPIRE TB): study protocol for a pragmatic randomised controlled trial.

Journal: BMC infectious diseases

Published: April 02, 2025

Showing 1-12 of 73

Last Updated: 09/26/2026